PMID: 16629420Apr 25, 2006Paper

Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation

Multiple Sclerosis : Clinical and Laboratory Research
M DaumerJ S Wolinsky

Abstract

Despite prolonged survival, patients with multiple sclerosis (MS) experience considerable morbidity, which adversely impacts quality of life. To assess the risk-benefit of a clinical trial of high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation for MS, we sought to determine the natural history of the disease in a comparison group of untreated patients. We identified 285 individuals with 2132 combined observation years (median: 5.6 years; 5th to 95th percentile: 1-21 years), with Expanded Disability Status Scale (EDSS) scores of 3.0-5.5 at baseline observation. Disease-related mortality was zero at five years, 5.4% at 10 years, and 22% at 15 years (40 patients contributing to the data point; 95% confidence interval: 4-32%). Risk for progression to advanced disability, defined as an EDSS score of 8, was very low for the subgroup with a baseline EDSS score of 3-3.5; however, for those with a baseline EDSS score of 4-5.5, 3% had advanced disability after two years, 5% after three years, 6% after four years, 12% after five years, and 40% after 10 years. The estimated probability of disease progression, defined as an increase in EDSS score by > or = 1.0 sustained for at least 180 days, was 5% a...Continue Reading

References

Dec 1, 1989·Controlled Clinical Trials·R JaeschkeG H Guyatt
Feb 1, 1993·Brain : a Journal of Neurology·B Runmarker, O Andersen
Apr 29, 1999·Brain : a Journal of Neurology·P Rudge
Sep 1, 1999·Multiple Sclerosis : Clinical and Laboratory Research·B G Weinshenker
May 20, 2000·JAMA : the Journal of the American Medical Association·E J EmanuelC Grady
Nov 18, 2000·The New England Journal of Medicine·C ConfavreuxP Adeleine
Jan 18, 2002·The New England Journal of Medicine·Donald W Paty, Douglas L Arnold
Jan 24, 2002·Neurology·D S GoodinUNKNOWN Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Pra
Jul 20, 2002·Clinical Neurology and Neurosurgery·John BenedikzKāri Stefánsson
Aug 27, 2002·Journal of Neurology·A FassasUNKNOWN Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation)
Sep 21, 2002·Journal of Neurology·Reinhard Hohlfeld
Dec 31, 2002·Lancet·Hans-Peter HartungUNKNOWN Mitoxantrone in Multiple Sclerosis Study Group (MIMS)
Feb 1, 2003·Lancet·John NoseworthyMartin Daumer
Jul 15, 2003·Current Opinion in Neurology·Paolo A MuraroRoland Martin
Oct 15, 2003·Blood Reviews·Athanasios Fassas, Vassilios K Kimiskidis
Jan 28, 2004·Neurology·Mark S Freedman, Harold L Atkins
Feb 13, 2004·Brain : a Journal of Neurology·Henrik Brønnum-HansenEgon Stenager
Feb 24, 2004·Journal of Hematotherapy & Stem Cell Research·Athanasios Fassas, Aristide Kazis
Jul 21, 2004·Journal of the Neurological Sciences·Athanasios Fassas, Vasilios K Kimiskidis
Aug 11, 2004·Best Practice & Research. Clinical Haematology·Athanasios Fassas, Richard Nash
Aug 11, 2004·Best Practice & Research. Clinical Haematology·Christopher N Bredeson, Steven Z Pavletic
Nov 19, 2004·Journal of Neurology·Peter Rieckmann

❮ Previous
Next ❯

Citations

Jun 10, 2010·Journal of Neurology·Saud A SadiqLauren M Puccio
Jul 14, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Jochen C UlzheimerHeinz Wiendl
Oct 30, 2008·Autoimmunity·Athanasios Fassas, Gian Luigi Mancardi
Nov 19, 2010·Expert Review of Hematology·Claudio AnnaloroGiorgio Lambertenghi Deliliers
Mar 14, 2020·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Alice MariottiniPaolo A Muraro
Nov 26, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Marco CapobiancoA Bertolotto
Dec 21, 2010·Current Opinion in Oncology·Daniel Harrison, Douglas E Gladstone
Sep 7, 2007·Journal of Neuropathology and Experimental Neurology·Jeroen J G GeurtsPaul van der Valk
Aug 10, 2019·Multiple Sclerosis : Clinical and Laboratory Research·Adam FambiatosTomas Kalincik
Apr 12, 2017·CNS Drugs·Pamela SarkarNeil J Scolding
Nov 20, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Pietro IaffaldanoUNKNOWN Italian MS Register

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.